Biology Reference
In-Depth Information
[24] Vanhove B, Laflamme G, Coulon F, Mougin M, Vusio P, Haspot F, et al. Selective block-
ade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody.
Blood 2003;102:564-70.
[25] Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J. Superhumanized anti-
bodies: reduction of immunogenic potential by complementarity-determining region
grafting with human germline sequences: application to an anti-CD28. J Immunol
2002;169:1119-25.
[26] Jang MS, Pan F, Erickson LM, Fisniku O, Crews G, Wynn C, et al. A blocking anti-CD28-
specific antibody induces long-term heart allograft survival by suppression of the PKC
theta-JNK signal pathway. Transplantation 2008;85:1051-5.
[27] Shiao SL, McNiff JM, Masunaga T, Tamura K, Kubo K, Pober JS. Immunomodulatory
properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and
antagonistic activities. Transplantation 2007;83:304-13.
[28] Raychaudhuri SP, Kundu-Raychaudhuri S, Tamura K, Masunaga T, Kubo K, Hanaoka K,
et al. FR255734, a humanized, Fc-silent, anti-CD28 antibody, improves psoriasis in the
SCID mouse-psoriasis xenograft model. J Invest Dermatol 2008;128:1969-76.
[29] Beyersdorf N, Ding X, Blank G, Dennehy KM, Kerkau T, Hunig T. Protection from
graft-versus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28
monoclonal antibody. Blood 2008;112:4328-36.
[30] Yu XZ, Albert MH, Martin PJ, Anasetti C. CD28 ligation induces transplantation toler-
ance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J Clin
Invest 2004;113:1624-30.
[31] Mirenda V, Jarmin SJ, David R, Dyson J, Scott D, Gu Y, et al. Physiologic and aberrant
regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood
2007;109:2968-77.
[32] Dengler TJ, Szabo G, Sido B, Nottmeyer W, Zimmerman R, Vahl CF, et al. Prolonged
allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after
high-responder rat heart transplantation. Transplantation 1999;67:392-8.
[33] Haspot F, Villemain F, Laflamme G, Coulon F, Olive D, Tiollier J, et al. Differential effect
of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted
responses. Blood 2002;99:2228-34.
[34] Beyersdorf N, Ding X, Hunig T, Kerkau T. Superagonistic CD28 stimulation of allogeneic
T cells protects from acute graft-versus-host disease. Blood 2009;114:4575-82.
[35] Kitazawa Y, Fujino M, Li XK, Xie L, Ichimaru N, Okumi M, et al. Superagonist CD28 anti-
body preferentially expanded Foxp3-expressing nTreg cells and prevented graft-versus-
host diseases. Cell Transplant 2009;18:627-37.
[36] Albert MH, Yu XZ, Martin PJ, Anasetti C. Prevention of lethal acute GVHD with an
agonistic CD28 antibody and rapamycin. Blood 2005;105:1355-61.
[37] Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, et al.
Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med
1999;340:1704-14.
[38] Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, et al.
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.
Nature 1999;397:263-6.
[39] Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, et al. T-cell
co-stimulation through B7RP-1 and ICOS. Nature 1999;402:827-32.
[40] Coyle AJ, Lehar S, Lloyd C, Tian J, Delaney T, Manning S, et al. The CD28-related
molecule ICOS is required for effective T cell-dependent immune responses.
Immunity 2000;13:95-105.
[41] Gigoux M, Shang J, Pak Y, Xu M, Choe J, Mak TW, et al. Inducible costimulator pro-
motes helper T-cell differentiation through phosphoinositide 3-kinase. Proc Natl Acad
Sci USA 2009;106:20371-6.
[42] Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, et al. ICOS co-
stimulatory receptor is essential for T-cell activation and function [comment]. Nature
2001;409:97-101.
[43] Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in
costimulatory signals regulating T cell function. Nat Immunol 2001;2:203-9.
[44] Ozkaynak E, Gao W, Shemmeri N, Wang C, Gutierrez-Ramos JC, Amaral J, et al. Impor-
tance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection.
[comment]. Nat Immunol 2001;2:591-6.
[45] Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ. CD28 controls differentiation of regulatory
T cells from naive CD4 T cells. J Immunol 2008;181:2285-91.
[46] Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe AH, Noelle RJ, Rudensky AY,
et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-
regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic
bone marrow (BM). Blood 2005;105:3372-80.
216
Search WWH ::
Custom Search